Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hypertension

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 35 articles:
HTML format



Single Articles


    May 2022
  1. SUN Y, Mu J, Wang DW, Ouyang N, et al
    A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial.
    Lancet. 2022;399:1964-1975.
    PubMed     Abstract available


    April 2022
  2. FIZAZI K, Foulon S, Carles J, Roubaud G, et al
    Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design.
    Lancet. 2022;399:1695-1707.
    PubMed     Abstract available


  3. JAFAR TH, Jabbour S
    Village doctors managing hypertension in rural China.
    Lancet. 2022 Apr 29. pii: S0140-6736(22)00424.
    PubMed    


  4. MAHFOUD F, Kandzari DE, Kario K, Townsend RR, et al
    Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Lancet. 2022;399:1401-1410.
    PubMed     Abstract available


  5. SARATHY H, Salman LA
    Can renal denervation replace medications for patients with hypertension?
    Lancet. 2022;399:1363-1365.
    PubMed    


  6. WALD NJ, Law M, Morris J, Wald DS, et al
    Blood pressure meta-analysis highlights an implementation gap.
    Lancet. 2022;399:1379-1380.
    PubMed    


    November 2021
  7. CAVENDER MA, Wirka RC
    Blood pressure lowering in the prevention of type 2 diabetes.
    Lancet. 2021;398:1778-1779.
    PubMed    


  8. NAZARZADEH M, Bidel Z, Canoy D, Copland E, et al
    Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
    Lancet. 2021;398:1803-1810.
    PubMed     Abstract available


  9. GARRISON SR, McCormack J
    Blood pressure treatment: how low should you go?
    Lancet. 2021;398:1684.
    PubMed    


    September 2021
  10. PEARLMAN B, Lodebo BT
    Renin secreting tumour: a rare cause of secondary hypertension.
    Lancet. 2021;398:1074.
    PubMed    


  11. KAHAN T
    Low-dose combination of blood pressure-lowering medicines.
    Lancet. 2021;398:1022-1023.
    PubMed    


  12. NGUYEN TN, Chow CK
    Global and national high blood pressure burden and control.
    Lancet. 2021;398:932-933.
    PubMed    


  13. JAFFAR S, Ramaiya K, Karekezi C, Sewankambo N, et al
    Controlling diabetes and hypertension in sub-Saharan Africa: lessons from HIV programmes.
    Lancet. 2021 Sep 7. pii: S0140-6736(21)01731.
    PubMed    


    August 2021
  14. CHOW CK, Atkins ER, Hillis GS, Nelson MR, et al
    Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
    Lancet. 2021 Aug 27. pii: S0140-6736(21)01922.
    PubMed     Abstract available


  15. JACKSON R, Wells S
    Time to remove hypertension from our vocabulary?
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01916.
    PubMed    



  16. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01921.
    PubMed     Abstract available



  17. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.
    Lancet. 2021 Aug 24. pii: S0140-6736(21)01330.
    PubMed     Abstract available


    July 2021
  18. AFIFI T, Obeid M, Abdelati M, Almoqaid A, et al
    WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study.
    Lancet. 2021;398 Suppl 1:S3.
    PubMed     Abstract available


  19. EL-QATRAWI KJ
    Effect of hypertension on pregnancy outcomes at UNRWA health centres in Gaza governorates: a comparative study.
    Lancet. 2021;398 Suppl 1:S26.
    PubMed     Abstract available


    May 2021
  20. BROUWERS S, Sudano I, Kokubo Y, Sulaica EM, et al
    Arterial hypertension.
    Lancet. 2021 May 18. pii: S0140-6736(21)00221.
    PubMed     Abstract available


  21. AZIZI M, Sanghvi K, Saxena M, Gosse P, et al
    Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
    Lancet. 2021 May 14. pii: S0140-6736(21)00788.
    PubMed     Abstract available


  22. KAHAN T
    Decisions about antihypertensive treatment should focus on reducing cardiovascular risk.
    Lancet. 2021;397:1598-1599.
    PubMed    



  23. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    PubMed     Abstract available


    March 2021
  24. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    PubMed     Abstract available


    August 2020
  25. SCHWALM JD, McCready T, Islam S, McKee M, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4 - Authors' reply.
    Lancet. 2020;396:310-311.
    PubMed    


  26. RICHARDS A
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:310.
    PubMed    


  27. HENDRIKS M, van Andel J, Asiki G, Kyobutungi C, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:309-310.
    PubMed    


  28. O'SULLIVAN ED, MacIntyre IM
    Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER.
    Lancet. 2020;396:311.
    PubMed    


    July 2020
  29. CLUVER CA, Herbst P, Griffith-Richards S, Hassan M, et al
    Coarctation of the aorta: a rare cause of severe hypertension in pregnancy.
    Lancet. 2020;396:62.
    PubMed    


  30. REGAN J
    Collaborating on kidneys: Haiti's transplantation ambitions.
    Lancet. 2020;396:15-16.
    PubMed    


    June 2020
  31. STRONGMAN H, Lyon AR, Dos Santos Silva I, Smeeth L, et al
    Cancer and cardiovascular disease - Authors' reply.
    Lancet. 2020;395:1904-1905.
    PubMed    


  32. AHMED MA, Abdelnabi M, Almaghraby A, Elkafrawy FR, et al
    Neuropathy, encephalopathy, status epilepticus, and acute intermittent porphyria.
    Lancet. 2020;395:e101.
    PubMed    


    May 2020
  33. WILLIAMS B, Zhang Y
    Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19.
    Lancet. 2020 May 14. pii: S0140-6736(20)31131.
    PubMed    


    March 2020
  34. BOHM M, Kario K, Kandzari DE, Mahfoud F, et al
    Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.
    Lancet. 2020 Mar 27. pii: S0140-6736(20)30554.
    PubMed     Abstract available


  35. ZHOU F, Yu T, Du R, Fan G, et al
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
    Lancet. 2020 Mar 11. pii: S0140-6736(20)30566.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: